The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

The sky may be the limit for robotic cardiac surgery in 2026 and beyond.

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

The Amend device from Valcare Medical has a closed ring shape similar to the annuloplasty rings used to treat MR during open-heart surgeries. These early patients will be followed for a total of five years.

HighLife's new-look TMVR technology was designed to treat a wide range of patients. The two-part implant process includes a ring and a valve that centers itself inside that ring.

Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive. 

Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios.